Search results
Norman Edward "Ned" Sharpless (born September 20, 1966) is the previous Director of the National Cancer Institute (NCI). Before that, Sharpless was Professor of Medicine and Genetics Chair, Director of University of North Carolina UNC Lineberger Comprehensive Cancer Center , Molecular Therapeutics, Wellcome Distinguished Professorship in Cancer ...
Dec 7, 2021 · First person profile: Norman E. “Ned” Sharpless, MD. As director of the National Cancer Institute, Dr. Sharpless has turned a passion for research into a lifelong career. Ashley Hay BSN, RN. First published: 07 December 2021. https://doi.org/10.1002/cncr.34037.
- Ashley Hay BSN, RN
- 127, Issue24
- 07 December 2021
Norman E. Sharpless, M.D. (he/him) Director, National Cancer Institute. r. E. “Ned” Sharpless was officially sworn in as the as of of the Lineberger appointment, of North Comprehensive. Institute (NCI) on Dr. Sharpless Center at the University he held since 2014. Sharpless his undergraduate a Morehead mathematics. Medicine, graduating UNC ...
Apr 4, 2022 · Norman E. “Ned” Sharpless, M.D., announced today that he has decided to step down from his position as director of the National Cancer Institute (NCI), part of the National Institutes of Health, a position he has held since 2017. Dr. Sharpless will continue as NCI director through April 29, 2022, to allow for a thorough transition.
Apr 4, 2022 · Norman E. “Ned” Sharpless, M.D., announced today that he has decided to step down from his position as director of the National Cancer Institute (NCI), part of the National Institutes of Health, a position he has held since 2017.
Apr 4, 2022 · President Joe Biden will get a chance to name a new head of U.S. cancer fighting efforts. Norman “Ned” Sharpless, director of the $6.9 billion National Cancer Institute (NCI) since late 2017, announced today that he will step down at the end of this month after nearly 5 years on the job.
Senescence in health and disease. S He, NE Sharpless. Cell 169 (6), 1000-1011. , 2017. 1433. 2017. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16 INK4a. V Janzen, R Forkert, HE Fleming, Y Saito, MT Waring, DM Dombkowski, ...
